BAIYUNSHAN PH (00874.HK): Subsidiary to Raise Up to RMB6bn in Public Listing and Share Issue

On 15 Nov 2026, BAIYUNSHAN PH (00874.HK) sent a circular on its unit's RMB6bn share issue, diluting its stake from 90.92% to at least 53.23%.

NewTimeSpace News: On 15 November 2026, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (stock code: 874) published a circular on a major transaction involving a proposal for its subsidiary, which is listed on the National Equities Exchange and Quotations, to bring in strategic investors through a public listing on the Guangzhou Equity Exchange and to carry out a targeted share issue.

The subsidiary plans to issue no more than 1,734,104,046 new shares to industrial and financial investors, with subscribers taking up no more than 41.46% of its enlarged share capital and no single investor holding more than 15%. Fundraising is capped at RMB6 billion and open to no more than 15 investors, with consortium bids not accepted. The listing price is based on an independent valuer's income-approach valuation of the subsidiary's total equity value at RMB8.46 billion, divided by its 2,449,305,500 existing shares, giving a floor of RMB3.46 per share.

Proceeds will be used entirely in the subsidiary's business: up to RMB5.5 billion, or 91.67%, to repay bank borrowings and up to RMB500 million, or 8.33%, for working capital, both expected to be spent within 12 months of receipt.

After completion, the Company's interest in the subsidiary will be diluted from 90.92% to not less than 53.23%, and it will remain the controlling shareholder with no change in consolidation scope. Under Rule 14.29 the issue is a deemed disposal of an interest in a subsidiary, and on the maximum issue size one or more applicable percentage ratios will be above 25% but below 75%, making it a major transaction subject to reporting, announcement, circular and shareholder approval.

An extraordinary general meeting will be held at 10:00 am on 1 December 2026 at the Company's meeting room in Liwan District, Guangzhou, to approve the proposed mandate. Final investors are not yet determined and no agreement has been reached on board size or director nomination rights; if a final investor is a connected person, the issue would also be a connected transaction.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.